[HTML][HTML] Phase I study of single-agent anti–programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic …

JR Brahmer, CG Drake, I Wollner… - Journal of clinical …, 2010 - ncbi.nlm.nih.gov
JR Brahmer, CG Drake, I Wollner, JD Powderly, J Picus, WH Sharfman, E Stankevich…
Journal of clinical oncology, 2010ncbi.nlm.nih.gov
Purpose Programmed death-1 (PD-1), an inhibitory receptor expressed on activated T cells,
may suppress antitumor immunity. This phase I study sought to determine the safety and
tolerability of anti–PD-1 blockade in patients with treatment-refractory solid tumors and to
preliminarily assess antitumor activity, pharmacodynamics, and immunologic correlates.
Abstract
Purpose
Programmed death-1 (PD-1), an inhibitory receptor expressed on activated T cells, may suppress antitumor immunity. This phase I study sought to determine the safety and tolerability of anti–PD-1 blockade in patients with treatment-refractory solid tumors and to preliminarily assess antitumor activity, pharmacodynamics, and immunologic correlates.
ncbi.nlm.nih.gov